Genentech: Dan Sutherlin | Vice President, Small Molecule Discovery Chemistry

A link to this page has been copied to your clipboard.

https://www.gene.com/scientists/our-scientists/dan-sutherlin

Paste this link in an email to share.

Ok

Scientists / Our Scientists

Years at Genentech

Publications

I started at Genentech in 1999 in what was then the Bioorganic Chemistry Department. I was attracted to Genentech based primarily on the people that were here, their enthusiasm for science, and the opportunity to work closely with world-class biologists. Since that time I have enjoyed the experience of working in many therapeutic areas (cardiovascular, oncology, immunology, and neuroscience) and on many different target classes including kinases, proteases, integrins, and ion-channels. In each project there have always been new and interesting challenges to overcome that has kept me curious about and engaged in the science of drug discovery.

Featured Publication

Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer.

J. Med. Chem. 2011, 54:7579.

Daniel P Sutherlin, Linda Bao, Megan Berry, Georgette Castanedo, Irina Chuckowree, Jenna Dotson, Adrian Folks, Lori Friedman, Richard Goldsmith, Janet Gunzner, Timothy Heffron, John Lesnick, Cristina Lewis, Simon Mathieu, Jeremy Murray, Jim Nonomiya, Jodie Pang, Niel Pegg, Wei Wei Prior, Lionel Rouge, Laurent Salphati, Deepak Sampath, Qingping Tian, Vickie Tsui, Nan Chi Wan, Shumei Wang, Binqing Wei, Christian Wiesmann, Ping Wu, Bing-Yan Zhu, Alan Olivero.

View Abstract on PubMed

I am currently the research and development project leader of a new and exciting Pain target. Mutations in this ion channel have profound effects on pain.

The chance to participate in such an exciting area of science while being focused on a serious unmet medical need has been motivating.

Correction to: Safety, Tolerability, and Pharmacokinetics of GDC-0276, a Novel NaV1.7 Inhibitor, in a First-in-Human, Single- and Multiple-Dose Study in Healthy Volunteers (Clinical Drug Investigation, (2019), 10.1007/s40261-019-00807-3)

Clinical Drug Investigation, ISSN: 11791918 11732563

Michael E. Rothenberg; Tagen; Jae H. Chang; Janel Boyce-Rustay; Michel Friesenhahn; David Hackos; Avis Hains; Dan Sutherlin; Michael Ward; William Cho

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page.

A link to this page has been copied to your clipboard.

Dan Sutherlin

Vice President, Small Molecule Discovery Chemistry

Featured Publication

Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer.